Liminatus Pharma Inc. LIMN
4.20
0.02
0.48%
as of 25 Sep
- Market cap
- $5.6M
- P/E
- 0.0×
Follow LIMN
| Dec '25 | Dec '24 | |
|---|---|---|
Current Ratio |
0.05 | 0.21 |
Net Debt/EBITDA |
(0.37) | (5.98) |
Debt/Assets |
281.30% | 369.26% |
Debt/Equity |
(0.15) | (1.03) |
Asset Turnover |
0.00 | — |
Operating CF/Net income |
0.98 | 0.41 |
Capex/Depreciation |
(7.28) | — |
Interest Coverage |
0.00 | 0.00 |
| 70.02% | 0.00% | |
| (344.72%) | 0.00% | |
ROIC |
0.00% | (360.95%) |
Return on Tangible Assets |
104.30% | 18.22% |
Average Days of Receivables |
— | 0.00 |
Research and Development Expense of Revenue |
— | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Free Cash Flow per Share |
(21.00) | (4.15) |
Cash per Share |
0.71 | 0.16 |
Shareholders Equity per Share |
(20.66) | (55.26) |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
(20.66) | (55.26) |
Free Cash Flow |
(9.98) | (1.45) |
Working Capital |
(9.80) | (19.47) |
Capital Expenditures |
(0.01) | — |
Net Current Asset Value |
(9.83) | (19.47) |
| Other line items | ||
Quick Ratio |
0.03 | 0.15 |
Depreciation/Fixed assets |
0.15 | 0.00 |
Cash ROIC |
124.16% | (210.68%) |
Accounts Payable Turnover |
0.00 | — |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(20.97) | (4.15) |
Capex per Share |
(0.03) | 0.00 |
Average Payables |
1.03 | — |
Average Assets |
2.96 | — |
Average Common Equity |
(14.58) | — |
Capex to Sales |
0.00 | — |
Net Profit Margin |
0.00% | 0.00% |
Columns are period end dates